Court Says FibroGen’s UK Roxadustat Patents Are Invalid
Ruling Favors Akebia/Otsuka’s Rival Anemia Drug
Executive Summary
A complex and weighty judgment from the High Court regarding a new class of anemia compounds tackles a range of thorny patent law issues including obviousness, insufficiency and indirect infringement.
You may also be interested in...
Vadadustat Emerges As Japan HIF-PHI Contender With First Filing Globally
Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.
COVID-19 Summit Sees Progress On Test-And-Treat, IP Licensing, & Funding Commitments
Announcements at the second Global COVID-19 Summit included a technology licensing agreement for vaccine and diagnostic products developed by the US NIH, a new partnership to boost the use of testing and antiviral treatments in less wealthy countries, and a flurry of new funding pledges from organizations and companies alike.
EMA To Draw Up 'Critical Medicine' Lists For Future Health Crises
As part of its expanded mandate, the EU regulator is identifying those medicines whose supply will need to be closely monitored during health crisis situations. The lists will draw on various information sources, including real-world evidence databases.